Related Experiment Video
Updated: Nov 12, 2025

Quantification of Colonic Stem Cell Mutations
Published on: September 25, 2015
FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell
Sébastien Relier1, Julie Ripoll2, Hélène Guillorit1,3
1IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
Abstract:
Cancer stem cells (CSCs) are a small but critical cell population for cancer biology since they display inherent resistance to standard therapies and give rise to metastases. Despite accruing evidence establishing a link between deregulation of epitranscriptome-related players and tumorigenic process, the role of messenger RNA (mRNA) modifications in the regulation of CSC properties remains poorly understood. Here, we show that the cytoplasmic pool of fat mass and obesity-associated protein (FTO) impedes CSC abilities in colorectal cancer through its N6,2'-O-dimethyladenosine (m6Am) demethylase activity. While m6Am is strategically located next to the m7G-mRNA cap, its biological function is not well understood and has not been addressed in cancer. Low FTO expression in patient-derived cell lines elevates m6Am level in mRNA which results in enhanced in vivo tumorigenicity and chemoresistance. Inhibition of the nuclear m6Am methyltransferase, PCIF1/CAPAM, fully reverses this phenotype, stressing the role of m6Am modification in stem-like properties acquisition. FTO-mediated regulation of m6Am marking constitutes a reversible pathway controlling CSC abilities. Altogether, our findings bring to light the first biological function of the m6Am modification and its potential adverse consequences for colorectal cancer management.
Insights
Fat mass and obesity-associated protein (FTO) hinders cancer stem cell (CSC) abilities in colorectal cancer. Its demethylase activity on N6,2′-O-dimethyladenosine (m6Am) mRNA modifications is crucial for controlling CSC properties and chemoresistance.
Area of Science:
- Molecular Biology
- Cancer Biology
- Epigenetics
Background:
- Cancer stem cells (CSCs) drive tumor growth, metastasis, and therapy resistance.
- Epitranscriptomic modifications, including mRNA methylation, are increasingly linked to cancer.
- The role of N6,2′-O-dimethyladenosine (m6Am) and its regulation in CSCs is largely unknown.
Purpose of the Study:
- To investigate the function of the fat mass and obesity-associated protein (FTO) in regulating CSC properties.
- To elucidate the role of m6Am mRNA modification in colorectal cancer stemness and chemoresistance.
Main Methods:
- Analysis of FTO expression in patient-derived colorectal cancer cell lines.
- Assessment of m6Am levels on mRNA.
- In vivo tumorigenicity assays.
- Chemoresistance assays.
- Inhibition of m6Am methyltransferase PCIF1/CAPAM.
Main Results:
- Low FTO expression correlated with elevated m6Am levels in mRNA.
- Reduced FTO and increased m6Am enhanced in vivo tumorigenicity and chemoresistance of CSCs.
- Inhibition of PCIF1/CAPAM reversed the CSC phenotype, highlighting the role of m6Am.
Conclusions:
- FTO's cytoplasmic demethylase activity on m6Am regulates CSC abilities in colorectal cancer.
- m6Am modification is a novel regulator of stem-like properties and chemoresistance.
- Targeting the FTO-m6Am pathway offers a potential strategy for colorectal cancer management.
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Drugs that Stabilize Microtubules

